adenosine deaminase

Metabolic consequences of adenosine deaminase deficiency in mice are associated with defects in alveogenesis, pulmonary inflammation, and airway obstruction.

Adenosine A2B receptors behave as an alternative anchoring protein for cell surface adenosine deaminase in lymphocytes and cultured cells.

The human genes for S-adenosylhomocysteine hydrolase and adenosine deaminase are syntenic on chromosome 20.

Pleural Fluid Examination: Differential count and Lymphocyte/Neutrophil ratio by microscope, LDH, Activity of Adenosine deaminase by using commercial kit, Z N stain for AFB, protein concentration.

Role of adenosine deaminase in diagnosis of exudative type of pleural effusion.

Adenosine deaminase in the diagnosis of tuberculous pleural effusion.

Combined use of pleural adenosine deaminase with lymphocyte/neutrophil ratio: increased specificity for the diagnosis of tuberculous pleuritis.

This is compatible with her negative pleural adenosine deaminase result, negative culture, absence of pulmonary parenchymal disease, and negative pleural biopsy.

Long-term efficacy of enzyme replacement therapy for adenosine deaminase (ADA)-deficient severe combined immunodeficiency (SCID).

The serum adenosine deaminase (ADA) activity (P<0.

Pericardial effusion examination results showed a positive Rivalta test, protein concentration of 49 g/L, white blood cell (WBC) count of 6,400 x 10[sup]6/L with 78% mononuclear leukocytes and 22% multinuclear leukocytes, and adenosine deaminase (ADA) level of 84 U/L.

In June 2016, GlaxoSmithKline, Fondazione Telethon and Ospedale San Raffaele gained European Commission approval for Strimvelis (autologous CD34+ cells transduced to express ADA), the first ex-vivo stem cell gene therapy to treat patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID).

Pleural biopsy and adenosine deaminase enzyme activity in effusions of different aetiologies.

Since 1978, adenosine deaminase (ADA) has been used as a diagnostic test in tuberculous effusions.

GlaxoSmithKline (GSK), Fondazione Telethon (Telethon) and Ospedale San Raffaele (OSR) today announced that the European Commission has approved Strimvelis, the first ex-vivo stem cell gene therapy to treat patients with a very rare disease called ADA-SCID (Severe Combined Immunodeficiency due to Adenosine Deaminase deficiency).